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INTRODUCTION
============

According to the GLOBOCAN 2018 estimates of cancer incidence and mortality \[[@B1]\], the global incidence rate of thyroid carcinoma in men and women is 3.1 and 10.2 per 100,000, respectively, but mortality rates from the disease are much lower, with rates from 0.4 to 0.5 in men and women, suggesting that thyroid carcinoma generally shows indolent behavior. In particular, in Korea, the United States, and European countries, where thyroid cancer incidence has been rapidly increasing over the last few decades, mortality has steadily declined with the rise in the incidence of thyroid microcarcinomas.

The indolent behavior of thyroid carcinoma compared with other types of cancer can be explained by its genetic characteristics. A pan-cancer study using The Cancer Genome Atlas (TCGA) data showed that differentiated thyroid carcinoma (DTC) is a tumor with one of the lowest tumor mutational burdens, and usually harbors only a single driver gene alteration \[[@B2][@B3][@B4]\].

Meanwhile, the mutually exclusive mutation profile of thyroid carcinoma not only helps explain the indolent behavior of this cancer, but also indicates that single gene alterations, such as *BRAF* or *RAS* mutations, can induce the development or progression of cancer. Hence, it is expected that a deeper understanding of thyroid carcinoma may provide insights into tailored treatment for patients with such driver genes.

Recently, along with rapid developments of massively-parallel sequencing (MPS) technology \[[@B5]\], the genetic understanding of thyroid carcinoma has rapidly grown. TCGA found an association between the type of driver mutation and two distinct gene expression signatures in papillary thyroid carcinoma (PTC) \[[@B4]\]. Our group confirmed those results and expanded the scope of their analysis by including follicular thyroid carcinoma (FTC) as well as PTC \[[@B6]\].

In this review, we combine the results of genomic studies using MPS technology and describe (1) the types and frequencies of genomic alterations according to the histological phenotypes of DTC and (2) the characteristics and significance of the gene expression signatures of DTC.

CLASSIFICATION AND OVERVIEW OF FOLLICULAR CELL-DERIVED THYROID CARCINOMA
========================================================================

Follicular cell-derived thyroid carcinoma is classified into PTC (80% to 85%), FTC (10% to 15%), poorly-differentiated thyroid carcinoma (PDTC, \<2%), and anaplastic thyroid carcinoma (ATC, \<2%) \[[@B7]\]. The former two categories belong to DTC, and PTC accounts for most cases of DTC. PTC can be classified into various histologic subtypes, including classical PTC (cPTC) and follicular variant of PTC (FVPTC). In terms of molecular pathogenesis, the majority of DTC cases are caused by alterations of driver genes such as *BRAF*, *RAS*, or fusion genes \[[@B8]\]. Those alterations particularly activate the receptor tyrosine kinase (RTK)/mitogen-activated protein kinase (MAPK) pathway, a master regulator of numerous cellular processes including proliferation, differentiation, adhesion, migration, and apoptosis. DTC can progress to PDTC or ATC by additional hits on *TERT*, tumor suppressors, or phosphoinositide 3-kinase (PI3K) pathway genes.

GENOMIC CHARACTERISTICS OF CLASSICAL PTC
========================================

PTC is the most common type of thyroid carcinoma of follicular cell origin, and accounts for about 85% of cases of DTC \[[@B7]\]. It has been well documented that PTC develops through the activation of the RET/PTC-RAS-BRAF-ERK axis, which drives the oncogenic proliferation of thyroid follicular cells \[[@B9][@B10][@B11]\]. However, until recently, few in-depth genomic characterizations of PTC have been performed, despite its high incidence, which might be because it shows less aggressive features than any other human cancers \[[@B12]\]. Since the first large-scale integrative genomic analysis was accomplished by TCGA in 2014 \[[@B4]\], several genomic studies of DTC using MPS have been published. We summarize the major findings of these studies in [Table 1](#T1){ref-type="table"}, and present the frequencies of genomic alterations of DTC in several representative studies in [Fig. 1](#F1){ref-type="fig"}.

In the TCGA study, classical, tall cell variant, and FVPTC from 496 patients (mostly consisting of Caucasians) were analyzed with diverse types of MPS and array-based technologies. This study discovered a novel thyroid cancer driver gene, *EIF1AX*, as well as well-known oncogenic drivers such as *BRAF*, *NRAS*, *HRAS*, and *KRAS*. In cPTC, the frequency of *BRAF*, *NRAS*, *HRAS*, and *KRAS* mutations was 55.25%, 4.01%, 1.54%, and 0.31%, respectively. *EIF1AX* plays a role in recognition of the translation initiation site, and cancer-related mutations in this gene alter gene expression by increasing discrimination against AUG codons in poor contexts \[[@B13]\]. *EIF1AX* was originally reported in uveal melanoma, and in most cases showed co-mutations with *GNA11* or *GNAQ* \[[@B14][@B15]\]. However, in PTC, *EIF1AX* was altered in a mutually exclusive manner with other known driver genes, and it was found in cPTC (0.62%) and FVPTC (3.03%), which are the two main types of PTC.

Furthermore, gene rearrangements including *RET* (8.02%), *BRAF* (2.47%), *NTRK1/3* (2.16%), *ALK* (1.23%), *PAX8-PPARG* (0.93%), *THADA* (0.31%), *FGFR2* (0.31%), and *LTK* (0.31%) were discovered in cPTC, and those alterations were also mutually exclusive with each other, in addition to mutations in *BRAF*, *H/K/NRAS*, and *EIF1AX*. In particular, patients who were diagnosed with PTC at a young age frequently harbored gene rearrangements, and this tendency has been confirmed by other reports \[[@B6][@B16]\].

In 2015, Costa et al. \[[@B17]\] described the RNA sequencing (RNA-seq)-based mutational and transcriptional profiles of 18 PTCs from French patients. They discovered somatic mutations in well-known driver genes including *BRAF* (16.67%), *RAS* (16.67%), and *RET* rearrangements (38.89%). Moreover, a novel fusion transcript, *WNK1-B4GALNT3*, was found, as well as somatic mutations in *DICER1* (5.56%), *MET* (5.56%), and *VHL* (5.56%).

In 2016, our group also described the mutational profile of 77 Korean patients with cPTC based on an RNA-seq analysis \[[@B6]\]. In our study cohort, 71.43% of cPTC patients harbored *BRAF*^V600E^, which is a slightly higher rate than has been reported in other studies \[[@B4][@B17][@B18][@B19][@B20]\]. An *NRAS* mutation was only found in 1.3% of study subjects, whereas 18.18% of cases of cPTC had gene rearrangements in *RET* (5.18%), *BRAF* (3.9%), *NTRK1/3* (3.9%), *ALK* (1.3%), *FGFR2* (1.3%), and *THADA* (1.3%).

Pan et al. \[[@B18]\] showed a different mutational spectrum from that observed in the TCGA study in a Chinese population using 402 PTC tumors (91 and 311 tumors analyzed by whole-exome sequencing \[WES\] and Sanger sequencing methods, respectively). As in the TCGA cohort, *BRAF*^V600E^ (59%) was the most recurrently identified driver mutation in Chinese PTC patients. However, they found that long non-coding RNA (*GAS8-AS1* \[9.2%\]), was the second most frequently altered gene, rather than *RAS* (3.2%), and proposed that it plays a tumor-suppressive role in PTC. Another frequently altered gene, G protein-coupled receptor *LPAR4* (2.7%), was also discovered, and the malignant transformation of PTC through *LPAR4* mutation was revealed. In 2017, another Chinese PTC cohort with 138 patients was analyzed using the targeted sequencing method \[[@B19]\]. This study displayed a similar incidence of *BRAF*^V600E^ (57.25%) as the TCGA cohort, whereas only 2.17% of tumors harbored a *RAS* mutation (*KRAS* only). Moreover, several gene rearrangements were identified, including *RET* (5.07%), *NTRK1/3* (2.17%), and *BRAF* (0.72%), as well as three novel fusion gene candidates, *UEVLD-RET*, *OSBPL9-BRAF*, and *SQSTM1-NTRK3*.

Furthermore, Siraj et al. \[[@B20]\] reported the genomic characteristics of 101 PTCs from Saudi Arabian patients by WES and validated their results using 785 additional samples. They proposed that *TG* co-mutation is co-implicated in patients with *BRAF*, *NRAS*, or *HRAS* mutations. In their study, *BRAF* and *RAS* (*HRAS* and *NRAS*) were the most frequently altered genes (59.54% and 8.13%, respectively) and *TG* was the third most frequently mutated gene (3.05%). Patients with a *TG* alteration showed poorer survival than individuals without this type of mutation. Moreover, they found that advanced PTC patients frequently harbored *TG* mutations (12.7%).

GENOMIC CHARACTERISTICS OF FTC
==============================

FTC is the second most common type of thyroid cancer following PTC, and accounts for 10% to 30% of cases of DTC \[[@B21]\]. However, research on the genomic and transcriptomic characteristics of the follicular histologic type of thyroid tumors, especially FTC, is still lacking. In 2016, our group reported a comprehensive study of the transcriptional and mutational landscape of follicular-patterned thyroid tumors, including follicular adenoma (FA), minimally-invasive FTC (miFTC), and FVPTC, as well as cPTCs \[[@B6]\]. We analyzed miFTC in 30 Korean patients using RNA-seq. Additionally, 25 FA tumors were sequenced, as FA is a benign lesion that is difficult to differentiate from FTC based on cytologic, sonographic, or clinical features \[[@B22]\]. This was the first research to broaden the molecular understanding of follicular-patterned thyroid tumors, including FTC.

We identified that miFTC and FA showed a similar mutational profile, and most tumors had single nucleotide-level alterations in *H/K/NRAS* (38.18%), *DICER1* (7.27%), *EIF1AX* (5.45%), *EZH1* (7.27%), *SPOP* (3.65%), *IDH1* (1.82%), and *SOS1* (1.82%), rather than fusion genes. Only one *PAX8-PPARG* (1.82%) translocation was found in our study cohort. All mutations were mutually exclusive with each other.

This study was the first to confirm the existence of *EIF1AX* mutations in miFTC, as well as in PTC. Moreover, FA harbored this type of mutation, as reported in another previous study \[[@B23]\]. Several mutations in *DICER1*, which is involved in the processing of miRNA precursor hairpins and long double-stranded RNA, were found \[[@B24]\]. *DICER1* has been reported to be associated with familial thyroid carcinoma and diverse types of cancer \[[@B25][@B26][@B27][@B28]\]. In our study, somatic *DICER1* mutations were especially common in the ribonuclease IIIb domain, and those mutations associated with gene expression levels of *DICER1*.

After our first report regarding *EZH1*^Q571R^ and *EZH1*^Y624F^ mutations in follicular thyroid tumors, *EZH1* was proposed to have an oncogenic impact when mutated as a second hit in autonomous thyroid adenomas \[[@B29]\]. This study reported that *EZH1* mutations were strongly associated with alterations in cAMP pathway genes, such as TSHR, GNAS, or *ADCY9*. Furthermore, functional validation showed increased histone H3 trimethylation and proliferation of thyroid cells with the *EZH1*^Q571R^ mutation.

An alteration of *SPOP* was originally reported to be found in 15% of prostate carcinomas \[[@B30][@B31][@B32]\], and this mutation was thought to be involved in the regulation of *DAXX* gene, which associates with transcriptional repressor proteins such as histone deacetylase II, core histones, and chromatin-associated proteins \[[@B33]\]. In our study, two FA samples harbored *SPOP*^P94R^, which is localized in the MATH domain, and the same mutation was repeatedly identified in subsequent studies \[[@B34][@B35]\]. Moreover, *IDH1*^R132C^ and *SOS1*^N233Y^ were found; these mutations have not been reported in thyroid carcinoma, but have been recurrently found in other types of cancer \[[@B36][@B37]\]. The aforementioned alterations of *DICER1*, *EIF1AX*, *EZH1*, *SPOP*, and *IDH1* imply that several other pathways may account for a substantial proportion of FTC/FA pathogenesis, rather than the MAPK and PI3K pathways.

Regarding copy number alterations, we found that follicular-patterned thyroid tumors---miFTC, FA, and FVPTC---harbored more frequent arm-level chromosomal alterations than cPTC. In particular, chromosome 22q deletion was frequent in miFTC/FA/FVPTC or *RAS*-mutated tumors. Furthermore, arm-level copy number alterations were more frequent in miFTC than in FA, which might indicate that FA is a preneoplastic condition prior to miFTC.

A subsequent study from Korea described the genomic landscape of 13 FTC and 14 FA tumors \[[@B35]\]. Jung et al. \[[@B35]\] analyzed somatic mutations and copy number alterations using WES and a comparative genomic hybridization microarray, respectively. In their results, FTC and FA displayed similar genomic features, as we previously described; *RAS* (29.63%) and *EIF1AX* (7.41%) were the most frequently altered genes. Moreover, *EZH1*^Q571R^, *EZH1*^Y642F^, and *SPOP*^R94R^, which were first suggested as driver genes of FTC/FA by our group, were also found \[[@B6]\]. Furthermore, their analysis regarding the evolutionary age of tumors found that FA tumors are as old as FTC tumors, which suggests a similarity between FTC and FA on the molecular level.

GENOMIC CHARACTERISTICS OF FVPTC
================================

FVPTC, a thyroid carcinoma with the nuclear features of PTC, but a follicular growth pattern rather than papillae \[[@B38]\], is another type of follicular-patterned thyroid tumor, in addition to FTC and FA \[[@B39]\]. Among all PTC variants, FVPTC is the most common subtype, and the incidence of FVPTC has increased from 20% to 30% of all cases of PTC over the last three decades in the USA \[[@B40]\].

In the TCGA study of PTC, 99 FVPTC patients (21.2%) were included among 496 PTC patients \[[@B4]\]. The mutational profile of FVPTC was characterized as *RAS*-dominant (29.29%), as was that of FTC/FA \[[@B6]\]. However, 15.15% of FVPTCs also had *BRAF*^V600E^, in contrast to FTC, which rarely harbors this mutation. Furthermore, gene rearrangements including *THADA* (5.05%), *RET* (4.04%), *BRAF* (3.03%), *ETV6-NTRK3* (1.01%), *PAX8-PPARG* (1.01%), *MET* (1.01%), and *FGFR2* (1.01%) were discovered. In FVPTC, these gene rearrangements were also mutually exclusive with *BRAF*^V600E^ and *RAS* mutations, as in cPTC. When network-based stratification was applied to explore somatic mutation-based PTC subtypes \[[@B41]\], FVPTC showed a significant association with a subtype with alterations in *RAS*, *PTEN*, *PPARG*, and *TSHR*. Somatic copy number alterations were found more frequently in FVPTC than in cPTC. Moreover, an isolated deletion of chromosome 22q, a region including *NF2* and *CHEK2*, was enriched in FVPTC compared to other subtypes of PTC, suggesting loss of these tumor suppressors (*NF2* and *CHEK2*). This result again implies a significant association between chromosome 22q and the development of follicular-patterned thyroid carcinoma (FTC/FA and FVPTC).

In our comprehensive genomic study of follicular-patterned thyroid tumors \[[@B6]\], we discovered that FVPTC showed an intermediate mutational status between cPTC and miFTC. Among a total of 48 FVPTCs, *RAS* mutations were predominant (47.9%), followed by the *BRAF*^V600E^ mutation (25.0%). Gene rearrangements, including *ETV6-NTRK3* (8.33%), *PAX8-PPARG* (2.08%), *EZR-ERBB4* (2.08%), *FGFR2* (2.08%), and *THADA* (2.08%), were detected in 16.7% of FVPTCs. We also confirmed that FVPTC had higher percentages of arm-level copy number alterations, especially 22q deletion, which is consistent with results from previous studies \[[@B4][@B42]\].

FVPTC presents either as an encapsulated or as an infiltrative neoplasm. Recently, owing to the excellent prognosis of the non-invasive subset of encapsulated FVPTC (EFVPTC), a new entity called "non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)" was proposed \[[@B43]\]. We were the first to report the integrated transcriptomic, genomic, and clinical characterization of subtypes of FVPTC \[[@B6][@B44]\], whereas previous studies, including the TCGA study, did not classify FVPTC by subtype. The mutational profiles of EFVPTC and infiltrative FVPTC were similar to those of FA/miFTC and cPTC, respectively. This is consistent with a previous study that reported that the oncogenic mutational profile of EFVPTC was very close to that of FA/FTC, while the oncogenic mutational profile of infiltrative FVPTC was in between that of FA/FTC and cPTC, although it was closer to the latter \[[@B45]\]. When EFVPTC was classified into two subtypes---NIFTP and invasive EFVPTC---according to capsular and vascular invasion, in NIFTP, the *BRAF*^V600E^ mutation was not found, but *RAS* mutations were present in 64.7% as the major alterations. In contrast, in invasive EFVPTC, the *BRAF*^V600E^ mutation was found in 38.5% of cases, a similar proportion to that in infiltrative FVPTC (38.9%). The proportion of *RAS* mutations (38.5% and 38.9%, respectively) was also similar between invasive EFVPTC and infiltrative FVPTC.

IMPACT OF *TERT* PROMOTER MUTATIONS IN DTC
==========================================

*TERT* promoter mutations have been suggested as a strong prognostic biomarker in thyroid carcinoma. *TERT* is a core subunit of the RNA component, *TERC* \[[@B46]\]. Its upregulation reactivates telomerase, thereby maintaining the length of telomeres in human cancer cells \[[@B47]\]. There are two hot spots in the promoter region of *TERT*: chr5, 1,295,228 C\>T and 1,295,250 C\>T, which are localized 124 and 146 base pairs upstream of the *TERT* transcription start site, respectively \[[@B48][@B49]\]. The prevalence of *TERT* promoter mutations in PTC and FTC was reported to be approximately 12% and 18%, respectively, and was more frequent in PDTC and ATC \[[@B50]\]. The frequency of these mutations in DTC appears to differ among countries, and the prevalence in Korea was lower than in other countries \[[@B51]\].

A relationship between the progression of thyroid carcinoma and these mutations was proposed in 2013 \[[@B52]\], and several studies have demonstrated an association between *TERT* promoter mutations and aggressive clinicopathological features of PTC \[[@B50][@B53]\]. In 2014, Xing et al. \[[@B54]\] were the first to prove the role of the genetic duet of *BRAF*^V600E^ and *TERT* promoter mutations in aggressive behavior and poor clinical outcomes of PTC. Remarkably, although it was reported that *TERT* promoter mutations in PTC without the *BRAF*^V600E^ mutation did not increase the risk of recurrence or mortality after multivariate adjustment, a significant increased effect of the *TERT* mutations was observed when *BRAF*^V600E^ was co-mutated \[[@B54][@B55][@B56]\].

Several studies have confirmed the synergetic effect of the coexistence of *TERT* promoter mutations and *BRAF*^V600E^ in PTC \[[@B57]\], which implies the possibility that coexisting *TERT* promoter and *RAS* mutations in follicular-patterned thyroid tumors may also play a significant role in tumor aggressiveness. However, few studies have investigated the prognostic effect of the coexistence of *TERT* promoter and *RAS* mutations \[[@B55][@B58]\] Therefore, the underlying strength of their association needs to be investigated further. In an unpublished analysis, we recently discovered that all nine widely-invasive FTCs, analyzed by WES and RNA-seq, harbored various types of *TERT* alterations, including promoter mutations, fusion genes, and upstream translocation \[[@B59]\]. Although further investigation is needed, this result suggests that *TERT* alterations may play a significant role in the progression of FTC and tumor aggressiveness.

MOLECULAR CLASSIFICATION OF DTC
===============================

The major implication of the TCGA study was the discovery of two molecular subtypes of PTC, *BRAF*^V600E^-like (BVL) and *RAS*-like (RL), based on 71 gene expression signatures \[[@B4]\]. These two molecular subtypes represent differential regulation of mRNA/protein signaling (MAPK and PI3K signaling pathways) and thyroid differentiation, regardless of the PTC subtype. This concept of a molecular level-based classification broadened the previous understanding of thyroid carcinoma, which was based on tumor histopathology or cytology \[[@B60]\]. The BVL subtype was strongly associated with *BRAF*^V600E^ and diverse fusion genes such as *BRAF*, *RET*, and *NTRK1/3*. Hence, it was usually associated with cPTC. In contrast, the RL subtype was related to mutations of *RAS* and *EIF1AX*, and fusion genes such as *PAX8-PPARG*, *FGFR2*, and *THADA*. The transcriptomic profile of FVPTC was frequently characterized by the RL molecular subtype. Based on the genomic findings of the TCGA study, it was suggested that a pathologic reclassification of follicular-patterned thyroid tumors is justified, meaning that FVPTC, which is currently a subtype of PTC, could be classified as FTC in the future.

The classification of thyroid carcinoma into BVL and RL subtypes according to molecular characteristics was replicated by Costa et al. \[[@B17]\] with differentially expressed gene analysis. They showed that the BVL (*BRAF*, *ETV6-NTRK3*, and *RET* fusions) and RL (*HRAS*, *DICER1*, *PAX8-PPARG*, and *WNK1-B4GALNT3*) subtypes were distinctively associated with types of altered genes.

The most noteworthy outcome of our 2016 investigation \[[@B6]\] was that the notion of molecular classification of thyroid carcinoma was extended. In addition to the BVL and RL subtypes established by TCGA, our analysis suggested a third molecular subtype, non-*BRAF*-non-*RAS* (NBNR), which was mainly associated with follicular-patterned thyroid tumors. In particular, alterations in *DICER1*, *EIF1AX*, *EZH1*, *IDH1*, *SPOP*, *PAX8-PPARG*, and *THADA* fusion represented the signature of NBNR. Thyroid tumors classified as NBNR showed low levels of MAPK signaling activation relative to the BVL and RL subtypes, whereas high thyroid differentiation and preserved metabolism were also identified. Intriguingly, most tumors with *EIF1AX* mutations and *PAX8-PPARG*, which were classified as RL in the TCGA study, were re-classified as NBNR in our analysis \[[@B4]\]. This result was confirmed using the TCGA cohort, as well as our Korean subjects.

The existence of the third molecular subtype, which is distinct from BVL and RL, provides further support for the relationship between the follicular histology of thyroid carcinoma and the alteration of diverse signaling pathways, rather than the MAPK or PI3K signaling pathways. Only few NBNR tumors displayed lymph node metastasis and extrathyroidal extension, unlike the BVL and RL subtypes, which demonstrates their benign and indolent nature. Recently, in benign thyroid nodules, *EZH1*^Q571R^ and *SPOP*^P94R^ mutations with distinctive transcriptomic features from BVL were found \[[@B34]\], which is consistent with our study.

CONCLUSIONS
===========

Since the release of the TCGA study of PTC in 2014, additional genomic studies of DTC using MPS have been published. In the genomic landscape, the most recurrently altered genes in DTC, which has a low mutational burden relative to other cancers, are *BRAF*, *RAS*, and fusion genes. Some novel driver candidates also have been identified. The frequency of these genomic alterations varies across the subtypes of DTC: cPTC, FVPTC, and FTC. Moreover, *TERT* promotor mutations are the most important alteration that contributes to the progression of DTC, particularly when co-mutated with *BRAF* or *RAS*. In the transcriptomic landscape, DTC can be classified according to its gene expression profile as BVL, RL, or NBNR. Each subtype is associated with mutations of different genes, and the intracellular pathways related to cell proliferation or invasiveness, including the MAPK pathway, show a pattern of gradual activation from NBNR to RL to BVL, resulting in more aggressive behavior. Recent advances in MPS have provided important insights into the molecular pathogenesis of DTC beyond its histological classification.
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###### Summary of Major Genomic Studies of Differentiated Thyroid Carcinoma Analyzed Using the Massively-Parallel Sequencing Method
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  Study                                                                                                                   Subtype                                                                                                                                                       Country (ethnicity)             Significance
  ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------- ---------------------------------------------------------------------------------------------------
  TCGA (2014) \[[@B4]\]                                                                                                   PTC (*n*=496)                                                                                                                                                 USA (mainly Caucasian)          The first integrative genomic analysis of thyroid carcinoma
  Illustrated the detailed mutational profile of PTC                                                                                                                                                                                                                                                                    
  Introduced the novel conception of a thyroid carcinoma classification (BVL and RL) based on molecular characteristics                                                                                                                                                                                                 
  Costa et al. (2015) \[[@B17]\]                                                                                          PTC (*n*=18)                                                                                                                                                  France (Caucasian)              Replicated the existence of the BVL and RL subtypes identified by TCGA in thyroid carcinoma
  Identified a novel fusion gene rearrangement, *WNK1-B4GALNT3*, in PTC                                                                                                                                                                                                                                                 
  Pan et al. (2016) \[[@B18]\]                                                                                            PTC (*n*=402)                                                                                                                                                 China (East Asian)              Identified a novel tumor suppressor, *GAS8-AS1*, and a driver gene, *LPAR4*, in PTC
  Yoo et al. (2016) \[[@B6]\]                                                                                             PTC (*n*=125)                                                                                                                                                 Korea (East Asian)              The first mutational and transcriptional profiling of FA and FTC
  FA (*n*=25)                                                                                                             Identified a third molecular subtype of thyroid carcinoma, NBNR                                                                                                                               
  FTC (*n*=30)                                                                                                            Revealed the benign characteristics and the similarity between three follicular-patterned thyroid carcinomas (miFTC, FA, and EFVPTC) at the molecular level                                   
  Siraj et al. (2016) \[[@B20]\]                                                                                          PTC (*n*=886)                                                                                                                                                 Saudi Arabia (Middle Eastern)   Identified an association between *TG* alterations and tumor aggressiveness in PTC
  Lu et al. (2017) \[[@B19]\]                                                                                             PTC (*n*=138)                                                                                                                                                 China (East Asian)              Identified novel fusion gene arrangements (*UEVLD-RET*, *OSBPL9-BRAF*, and *SQSTM1-NTRK3*) in PTC
  Jung et al. (2016) \[[@B35]\]                                                                                           FA (*n*=14)                                                                                                                                                   Korea (East Asian)              Revealed the molecular similarity between FTC and FA by analysis of evolutionary age of tumors
  FTC (*n*=13)                                                                                                                                                                                                                                                                                                          

TCGA, The Cancer Genome Atlas; PTC, papillary thyroid carcinoma; BVL, *BRAF*^V600E^-like; RL, *RAS*-like; FA, follicular adenoma; FTC, follicular thyroid carcinoma; NBNR, non-*BRAF*-non-*RAS*; miFTC, minimally-invasive follicular thyroid carcinoma; EFVPTC, encapsulated follicular variant of papillary thyroid carcinoma.
